On February 28, 2025, BridgeBio Pharma issued $575 million in 1.75% Convertible Senior Notes due 2031, raising approximately $563 million after expenses, and used part of the proceeds to repurchase shares and repay debt. The company plans to use remaining funds for general corporate purposes.